Summary by Futu AI
On May 8, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2024, along with updates on its business operations. The company reported a strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, while collaboration expenses increased due to commercial and manufacturing costs. The net loss for the quarter was $116.6 million, a significant increase from the previous year's $53.1 million. CRISPR Therapeutics highlighted the global activation of over 25 treatment centers for its gene-edited cell therapy, CASGEVY™, and the collection of cells from multiple patients. The company also discussed ongoing clinical trials for its next-generation CAR T product candidates, CTX112™ and...Show More